Bladder Cancer - Results from #680

REVIEW UroToday

Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1). December 20, 2023

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential. December 20, 2023

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. December 19, 2023

Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer. December 19, 2023

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab. December 18, 2023

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. December 18, 2023

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. December 18, 2023

PADCEV® (Enfortumab Vedotin-ejfv) with KEYTRUDA® (Pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer December 16, 2023

FDA Approves Expanded Indication for KEYTRUDA® (Pembrolizumab) Plus Padcev® (Enfortumab Vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer December 16, 2023

Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer. December 15, 2023

Global research trends of the application of artificial intelligence in bladder cancer since the 21st century: a bibliometric analysis. December 15, 2023

Immune Predictors of Response after Bacillus Calmette-Guérin Treatment in Non-Muscle-Invasive Bladder Cancer. December 14, 2023

Interruptions in bladder cancer care during the COVID-19 public health emergency. December 14, 2023

A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer. December 13, 2023

Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis. December 13, 2023

Bladder Cancer and Probiotics: What Do We Know So Far? December 12, 2023

Technical comparison of Abbott's UroVysion® and Biocare's CytoFISH urine fluorescence in situ hybridization (FISH) assays. December 12, 2023

Vesical imaging reporting and data system (VI-RADS) could predict the survival of bladder-cancer patients who received radical cystectomy. December 11, 2023

Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort. December 11, 2023

Environmental and Occupational Exposures and Prognosis in Patients with Non-Muscle Invasive Bladder Cancer in the Be-Well Study. December 8, 2023

Page 35 of 517